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Abstract We studied the role of Rho kinase and extracellular
signal-regulated kinase (ERK)-2 in the polarization and migra-
tion of T lymphocytes in response to the CCR7 ligands EBI1
ligand chemokine (ELC; CCL19) and secondary lymphoid-tis-
sue chemokine (SLC; CCL21). Both Rho kinase protein iso-
forms are expressed in T lymphocytes. Inhibition of the Rho
kinases with Y-27632 strongly inhibited SLC- and ELC-induced
polarized morphology and chemotaxis of T lymphocytes.
Although the chemokines induced ERK-2 activation, the block-
ade of this signaling pathway showed no e¡ect on polarization
and migration. This study indicates an important role of Rho
kinase in CCR7-mediated polarization and migration of T lym-
phocytes, whereas ERK-2 is not involved in these processes.
2 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Chemokine-mediated leukocyte migration is a multi-step
process involving dynamic and spatially regulated changes in
the cytoskeleton and cellular adhesion [1^5]. To initiate mi-
gration, the cells have to acquire a polarized morphology by
forming a leading lamellipodium and a trailing uropod [5].
When chemokines bind to their receptors, the heterotrimeric
Gi proteins are activated and the complex dissociates into its
K and LQ subunits. The released LQ subunit activates two ma-
jor signal transduction enzymes, phospholipase C, which gen-
erates two second messengers, inositol (1,4,5)-trisphosphate
and diacylglycerol, and phosphatidylinositol-3-OH kinase,
which generates phosphatidylinositol (3,4,5)-trisphosphate
and initiates the activation of downstream targets such as
protein kinase B and mitogen-activated protein kinases
(MAPKs) [6,7].
Recent attention has focused on the involvement of Rho
family GTPases and their downstream e¡ectors in chemokine-
elicited migration. Important Rho e¡ectors are the Rho-acti-
vated kinases, the so called Rho-associated coiled-coil forming
protein kinases (ROCK) I and II, which enhance myosin light
chain (MLC) phosphorylation by both inhibiting MLC phos-
phatase and phosphorylating MLC, thereby regulating actin^
myosin contraction [6,8]. It has been reported that the inhibi-
tion of the Rho kinases prevents MLC phosphorylation and
the chemotactic peptide-induced development of polarity, rear
detachment and migration in neutrophils [9,10], and blocks
eotaxin-induced chemotaxis in eosinophils [11]. Very recently,
the Rho^Rho kinase pathway has also been implicated in
lymphocyte responses mediated by SDF-1 (CXCL12) [12].
In the present study we have explored the function of the
Rho kinases and MAPK extracellular signal-regulated protein
kinase (ERK)-2 on the morphology and migration of blood T
lymphocytes in response to stimulation with the CCR7 ligands
EBI1 ligand chemokine (ELC; CCL19) and secondary lym-
phoid-tissue chemokine (SLC; CCL21). CCR7 is the chemo-
kine receptor that plays a central role in the homing and
tra⁄c of lymphocytes into and within secondary lymphoid
tissues. We show that both the CCR7-mediated polarization
and chemotaxis are dependent on the Rho kinases, but not on
ERK-2.
2. Materials and methods
2.1. Reagents and antibodies
Chemokines were chemically synthesized according to established
protocols [13]. Human interleukin (IL)-2 was kindly provided by Dr.
A. Lanzavecchia (Institute for Research in Biomedicine, Bellinzona,
Switzerland) and Y-27632 by Wel¢de Corporation (Osaka, Japan).
Stock solutions of Y-27632 (10 mM) were prepared in H2O and ali-
quots were stored at 4‡C. PD98059 was purchased from Calbiochem
(La Jolla, CA, USA) and phytohemagglutinin (PHA) from Murex
Biotech Ltd. (Dartford, Kent, UK). A polyclonal rabbit antibody
against amino acids 2^15 of p160 ROCK I was prepared as described
[14] and a monoclonal mouse anti-ROKK (ROCK II) antibody was
obtained from Transduction Laboratories (Lexington, KY, USA).
Alkaline phosphatase- and horseradish peroxidase-conjugated goat
anti-rabbit or anti-mouse IgG were obtained from Bio-Rad Labora-
tories (Hercules, CA, USA) and anti-ERK-2 (C14) from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).
2.2. Cells and culture
Peripheral blood lymphocytes were isolated from bu¡y coats of
donor blood (Central Laboratory of the Swiss Red Cross, Bern, Swit-
zerland) by centrifugation on Ficoll-Paque and Percoll gradients [15].
The cells were activated for 4^6 days by culturing in the presence of
1 Wg/ml PHA and 200 U/ml IL-2 in RPMI 1640 supplemented with
1% glutamine, non-essential amino acids, sodium pyruvate, 50 U/ml
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penicillin, 50 mg/ml streptomycin, 0.05 mM L-mercaptoethanol and
5% human serum (Swiss Red Cross Laboratory, Bern, Switzerland).
These cells are referred to as ‘T lymphocytes’. CEM cells, a human
lymphoblastoid CD4þ T cell line, were cultured in RPMI containing
10% fetal calf serum. Human platelets were isolated as previously
described [16].
2.3. Polarization
Cells (3U106/ml) were ¢xed in 1% glutaraldehyde for 30 min at
37‡C, washed once in phosphate-bu¡ered saline (PBS) and resus-
pended in PBS containing 1 mg/ml NaN3. Cell morphology was de-
termined with di¡erential interference contrast microscopy using a
Zeiss IM35 microscope with a 100U objective. Cell shape was deter-
mined by counting at least 100 cells per sample and classi¢ed accord-
ing to the following shape categories: spherical cells with a smooth
surface, non-polar cells and polarized cells [17].
2.4. Chemotaxis
Cell migration was assessed in 48-well chambers (Neuro Probe Inc.,
Cabin John, MD, USA) using polyvinylpyrrolidone-free polycarbon-
ate membranes (Poretics Corp., Livermore, CA, USA) with 3-Wm
pores [15]. Migration was allowed to proceed for 1 h and migrated
cells were counted at a 1000U magni¢cation in ¢ve ¢elds per well. All
determinations were performed in triplicate.
2.5. Immunodetection of ROCK I and II
Total protein samples of T lymphocytes, CEM cells and platelets
were prepared by TCA precipitation and separated by 11% SDS^
PAGE followed by transfer to Immobilon-P membrane. The mem-
branes were incubated with polyclonal rabbit anti-ROCK I or mono-
clonal mouse anti-ROCK II antibodies overnight. Enhanced chemilu-
minescence was used for detection of horseradish peroxidase-
conjugated secondary antibodies.
2.6. ERK-2 phosphorylation
T lymphocytes were serum-starved overnight in medium supple-
mented with 200 U/ml IL-2 [18]. The cells were then washed twice
and resuspended in HBSS containing 20 mM HEPES, pH 7.4. Stim-
ulation with the indicated chemokines was terminated after 2 min by
the addition of TCA. Total protein samples were separated by 11%
SDS^PAGE followed by transfer to Immobilon-P membrane. The
membrane was incubated with anti-ERK-2 antibodies overnight. En-
hanced chemiluminescence was used for detection of alkaline phos-
phatase-conjugated secondary antibodies.
Fig. 1. Immunodetection of ROCK I and II expression. Protein ex-
tracts of T lymphocytes, CEM cells and platelets were separated by
SDS^PAGE followed by transfer to Immobilon-P membrane and
immunodetection of the ROCK isoforms. The speci¢c antibodies to
ROCK I and ROCK II react with bands corresponding to a molec-
ular weight of about 160 kDa.
A B
C
Fig. 2. E¡ect of ROCK inhibition on chemokine-induced polarization of T lymphocytes. T lymphocytes were left untreated or exposed to
10 WM Y-27632 for 2 h at 37‡C and then further incubated for 30 min without addition (no chemokine, no CK) or in the presence of 300 nM
SLC or ELC. Cells were subsequently ¢xed with 1% glutaraldehyde and the polarity was determined. The photographs in panel A were ob-
tained with a di¡erential interference contrast Zeiss IM35 microscope. Arrowhead indicates the uropod and arrow the leading front of a typical
polarized cell (bar: 10 Wm). The data in panel B are mean valuesT S.D. from three independent experiments. C: The cells were exposed to in-
creasing concentrations of Y-27632 for 2 h at 37‡C and then further incubated for 30 min in the presence of 300 nM ELC and the polarity of
the ¢xed cells was determined. The data of one out of two independent experiments are shown.
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3. Results
3.1. Expression of ROCK I and II in T lymphocytes
To observe the presence of ROCK I and ROCK II in
T lymphocytes we performed Western blot analysis using spe-
ci¢c antibodies. Protein extracts from T lymphocytes and
CEM cells were separated by SDS^PAGE. Antibodies against
p160 ROCK (ROCK I) reacted with a band corresponding to
a molecular weight of about 160 kDa (Fig. 1, upper panel)
and an antibody against ROCK II with a band of a similar
molecular weight (Fig. 1, lower panel). A protein extract of
human platelets which were shown to express the Rho kinases
[9,14] was included as positive control.
3.2. E¡ect of ROCK inhibition on chemokine-induced
polarization of T lymphocytes
Polarization of T lymphocytes in response to stimulation
with the CCR7 ligands ELC (CCL19) and SLC (CCL21)
was determined by di¡erential interference contrast microsco-
py (Fig. 2A). About 20% of the T lymphocytes displayed a
bell-like, polarized morphology with a leading front and a
trailing uropod. On treatment with 300 nM SLC and ELC,
the extent increased to 55% (Fig. 2A,B). Pretreatment with the
selective ROCK inhibitor Y-27632 [19] markedly reduced the
number of polarized cells. Spontaneous and chemokine-in-
duced polarization was inhibited by 80^90%. Cells treated
with Y-27632 alone exhibited a round shape with ru¥es and
short protrusions that were observed in about 30% of the cells
(Fig. 2A), similar to e¡ects of Y-27632 on the morphology of
neutrophils [9]. As shown for the inhibition of ELC-induced
polarization of T lymphocytes in Fig. 2C, the e¡ect of
Y-27632 was concentration-dependent and already clearly de-
tectable at a concentration of 0.5 WM and reached maximal
levels at 10 WM.
Fig. 3. E¡ect of ROCK inhibition on chemokine-induced chemotax-
is of T lymphocytes. T lymphocytes were left untreated (closed
circles) or exposed to 20 WM Y-27632 (open circles) for 2 h at
37‡C. Chemotaxis was then determined in response to increasing
concentrations of SLC (A) and ELC (B). Shown are the average
numbers of migrated cells per ¢ve high-power ¢elds in triplicate
wells. The data are representative of three to ¢ve independent ex-
periments. Relative inhibition of migration after pretreatment with
10 WM Y-27632 in response to 300 nM SLC and ELC in T lympho-
cytes and CEM cells (C). Mean valuesT S.D. from three to seven
independent experiments.
Fig. 4. E¡ect of ERK inhibition on chemokine-induced polarization
and chemotaxis of T lymphocytes. T lymphocytes were left un-
treated or exposed to 50 WM PD98059 for 30 min at 37‡C and then
tested for ERK-2 activation (A), polarization (B) and chemotaxis
(C). A: After pretreatment, the cells were incubated for 2 min at
37‡C without addition (no chemokine, no CK) or in the presence of
100 nM SLC or ELC, and whole cell lysates were separated by
SDS^PAGE followed by transfer to Immobilon-P membrane and
immunodetection. Activated ERK-2 migrates with a slower electro-
phoretic mobility than non-activated ERK-2. The data are represen-
tative of three independent experiments. B: After pretreatment, the
cells were incubated for 30 min at 37‡C without addition (no che-
mokine, no CK) or in the presence of 300 nM SLC, ELC. Cells
were subsequently ¢xed with 1% glutaraldehyde and the polarity
was determined. Shown are the mean valuesT S.D. from four inde-
pendent experiments. C: After pretreatment, chemotaxis in response
to medium (no chemokine, no CK), 300 nM SLC, 300 nM ELC
was determined. Shown are the average numbersT S.D. of migrated
cells per ¢ve high-power ¢elds in triplicate wells. The data are repre-
sentative of three independent experiments.
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3.3. E¡ect of ROCK inhibition on chemokine-induced
chemotaxis of T lymphocytes
Y-27632 markedly inhibited chemotaxis of T lymphocytes
in response to increasing concentrations of the CCR7 ligands
(Fig. 3A,B). The inhibition after stimulation with 300 nM
ELC and SLC ranged from 70 to 75% (Fig. 3C). Under the
same conditions, a similar inhibitory e¡ect was obtained with
CEM cells (Fig. 3C). The data on polarization and chemotax-
is indicate that the ROCK kinases are involved in regulating
cell morphology and migration toward a chemokine gradient.
3.4. E¡ect of ERK inhibition on chemokine-induced
polarization and chemotaxis of T lymphocytes
Chemokine-induced activation of ERKs has been reported
to be critical for cell migration [20^22]. SLC and ELC acti-
vated ERK-2 in T lymphocytes, as shown in Fig. 4A. On
stimulation with the chemokines, ERK-2 is phosphorylated
on a threonine and a tyrosine residue by the MAP-ERK ki-
nase (MEK) and the double phosphorylated ERK-2 can be
detected on SDS^PAGE by its retarded electrophoretic mo-
bility (Fig. 4A, left panel). PD98059, a MEK-speci¢c inhibitor
[23], completely abrogated the chemokine-induced activation
of ERK-2 (Fig. 4A, right panel). We have, however, not ob-
served any inhibitory e¡ect of PD98059 on the polarization
(Fig. 4B) and chemotaxis (Fig. 4C) of the T lymphocytes
in response to stimulation with SLC, ELC. The data suggest
that these responses are not dependent on the activation of
ERK-2.
4. Discussion
In the present study we have shown the crucial role of Rho
kinases in CCR7-mediated polarization and migration of
T lymphocytes. Both Rho kinase isoforms, ROCK I and
ROCK II, were found to be expressed in T lymphocytes
and CEM cells, and their inhibition induced a profound im-
pairment of the chemokine-elicited cellular responses. The
MAPK kinase ERK-2 is activated by chemokine stimulation
in T lymphocytes, but it is not required for the regulation of
polarization and migration.
Migration and recruitment of T lymphocytes are largely
controlled by chemokines and their receptors, and are critical
at almost every step of immune responses [1,2,4]. These pro-
cesses require distinct changes and rearrangements in the cy-
toskeleton that are ruled by a very complex network of pro-
tein signals. Our ¢ndings show that the Rho kinases, which
are activated by small GTPases of the Rho family [6], play an
important and non-redundant role in the chemokine-induced
signaling, since the speci¢c inhibition of the kinases led to a
loss of CCR7-mediated polarization and chemotaxis of T lym-
phocytes. The data are in agreement with a recent study re-
porting that SDF-1 induced the activation of RhoA and
ROCK in lymphocytes, and that the inhibition of either of
them blocked chemotaxis in response to SDF-1 stimulation
[12]. It has also been shown that Rho kinase is involved in
CCR3-mediated signal transduction in eosinophils [11]. Che-
motaxis and reactive oxygen species production induced by
eotaxin, the speci¢c ligand for CCR3 [24], were inhibited by
Y-27632.
It is clear that chemokines induce the activation of the
MAPK ERK, but it is less clear whether ERK activation is
required for chemokine-induced chemotaxis [7]. It has been
reported that ERK-2 activation is involved in eotaxin-induced
chemotaxis of eosinophils [20,21] and in IP10-induced chemo-
taxis of hepatic stellate cells [22]. However, it has also been
reported that chemotaxis of neutrophils to IL-8 [25] and of
monocytes to MCP-1 [26] is independent of ERK-2 activa-
tion. Similar to these observations, we have found no e¡ect
on ERK-2 inhibition by PD98059 on the polarization and
chemotaxis of T lymphocytes in response to stimulation
with ELC and SLC as well as SDF-1 (data not shown). We
cannot rule out the possibility that ERK-2 is involved in a
discrete step in the complex process of the recruitment and
positioning of T lymphocytes. In conclusion our study delin-
eates a crucial role for Rho kinases, but not for MAPKs, in
the CCR7-mediated signaling that leads to lymphocyte polar-
ization and migration. In addition, the ¢ndings suggest that
the inhibition of Rho kinases can be a novel principle to
suppress the homing and recruitment of CCR7-positive lym-
phocytes.
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